Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC
Status:
Recruiting
Trial end date:
2025-12-18
Target enrollment:
Participant gender:
Summary
This is a randomized, controlled, phase 2 study to assess the efficacy and safety of ablation
followed by tislelizumab versus ablation alone in patients with early recurrent
hepatocellular carcinoma.